[T]he Initiative’s stakeholder survey and workshop are good first steps toward identifying major inefficiencies and potential solutions for alleviating regulatory and administrative burdens on cancer clinical trials.— Julie M. Vose, MD, MBA, FASCO
As reported in the Journal of Clinical Oncology, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, Omaha, and colleagues have provided a summary of the groundwork of an initiative by ASCO and the Association of American Cancer Institutes (AACI) to identify and reduce administrative and regulatory burdens in the conduct of cancer clinical trials.1 The initiative—Best Practices in Cancer Clinical Trials Initiative—is aimed at promoting practical solutions that meet existing regulatory and administrative requirements.
The initiative components described herein were overseen by a multidisciplinary working group of hematologists/oncologists, research nurses, administrators, managers, and industry representatives, with input from the U.S. Food and Drug Administration (FDA) and National Cancer Institute officials, contract research organization staff, and patient advocates. The primary components of the project thus far are a stakeholder survey to identify the most pressing issues in this area and an invitational workshop involving leading oncology professionals and policymakers aimed at identifying potential solutions. The report by Dr. Vose and colleagues summarized the stakeholder survey and workshop output.
The survey was sent in the fall of 2015 to approximately 1,200 physician-investigators, research staff, and administrators in academic and community-based research settings. A total of 310 responses were eligible for inclusion in the analysis. Physicians constituted 26% of the respondent pool, with the remaining 74% consisting of other research staff, including nurses, administrators, and managers.
The top three burdens identified by respondents were (1) contract negotiations with sponsors, contract negotiations with contract research organizations, and compliance with industry or contract research organization requirements in the area of getting clinical trials up and running; (2) site monitoring visits, management of regulatory documents, and external adverse event and serious adverse event reporting in the area of conducting trials; and (3) sponsor queries of databases and access to records, sponsor-required closeout activities, and long-term follow-up in the area of post-trial completion activities. In response to questions about adequacy of research staff, 58% of respondents indicated that they did not have adequate staffing to handle regulatory burden, and 41% reported not having adequate staffing to monitor regulatory compliance.
In the workshop, discussions on overcoming challenges with clinical trial contracts yielded the following potential solutions:
For problems with the preselection process:
For problems with the negotiation process:
For problems with inter- and intrainstitutional contracts:
ASCO and AACI continue to review the list of potential recommendations generated by workshop participants to determine ways that they can leverage ongoing efforts and develop new strategies to effectively and swiftly improve the conduct and management of cancer research.— Julie M. Vose, MD, MBA, FASCO, and colleagues
Discussions on improving clinical trial coverage analyses and budgeting yielded the following potential solutions:
For problems with coverage analysis of funded trials:
For problems with billing and coverage of procedures:
For problems with budgeting for infrastructure and research aspects of trials:
Discussions on complying with regulatory and training requirements yielded the following potential solutions:
For problems with adverse event and serious adverse event documentation and reporting:
For problems with auditing, monitoring site visits, trial queries, and documentation:
The authors concluded: “[T]he Initiative’s stakeholder survey and workshop are good first steps toward identifying major inefficiencies and potential solutions for alleviating regulatory and administrative burdens on cancer clinical trials. ASCO and AACI continue to review the list of potential recommendations generated by workshop participants to determine ways that they can leverage ongoing efforts and develop new strategies to effectively and swiftly improve the conduct and management of cancer research.” ■
Disclosure: Dr. Vose has had a consulting or advisory role with Bio Connections and has received (institutional) research funding from Celgene, Genentech, Incyte, Janssen Biotech, Acerta Pharma, Kite Pharma, Seattle Genetics, Novartis, Amgen, Bristol-Myers Squibb, and Allos Therapeutics. For full disclosures of the other study authors, visit jco.ascopubs.org.
1. Vose JM, Levit LA, Hurley P, et al: Addressing administrative and regulatory burden in cancer clinical trials: Summary of a stakeholder survey and workshop hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes. J Clin Oncol. September 6, 2016 (early release online).